The IARC TP53 database: new online mutation analysis and recommendations to users.

Hum Mutat

Molecular Carcinogenesis Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.

Published: June 2002

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.10081DOI Listing

Publication Analysis

Top Keywords

iarc tp53
8
recommendations users
8
mutation patterns
8
database
6
mutation
5
tp53 database
4
database online
4
online mutation
4
mutation analysis
4
analysis recommendations
4

Similar Publications

[New insights into the nature and classification of myelodysplastic neopmasm].

Zhonghua Yi Xue Za Zhi

December 2024

Department of Hematology, General Hospital, Tianjin Medical University, Tianjin300052, China.

The World Health Organization's (WHO) International Agency for Research on Cancer (IARC) released the fifth edition of the Classification of Tumors of the Hematopoietic and Lymphoid Tissues, renaming myelodysplastic syndrome (MDS) to myelodysplastic neoplasm (still abbreviated as MDS). This new classification integrates next-generation sequencing data to standardize the disease's nature. The name change reflects a deeper understanding of the disease, transitioning from the vague "syndrome" to a clearly defined neoplastic disease.

View Article and Find Full Text PDF
Article Synopsis
  • Metastatic Pituitary neuroendocrine tumors (PitNET) are rare and aggressive, making them difficult to treat; however, aggressive behavior is also observed in non-metastatic forms.
  • A study at UCSF analyzed samples from multiple patients with different types of aggressive PitNETs, categorizing them according to international neuroendocrine neoplasm criteria and identifying various tumor lineages.
  • High rates of disease progression and mortality were noted, along with concerning histopathological and molecular characteristics that could serve as indicators of tumor aggressiveness, suggesting a need for a new grading system.
View Article and Find Full Text PDF

Breast cancer (BC) has different molecular subgroups related to different risks and treatments. Tumor biopsies for BC detection are invasive and may not reflect tumor heterogeneity. Liquid biopsies have become relevant because they might overcome these limitations.

View Article and Find Full Text PDF

Gastric cancer is one of the most prevalent types of cancer worldwide. The World Health Organization (WHO), the International Agency for Research on Cancer (IARC), and the Global Cancer Statistics (GLOBOCAN) reported an age standardized global incidence rate of 9.2 per 100,000 individuals for gastric cancer in 2022, with a mortality rate of 6.

View Article and Find Full Text PDF

MASLD and aspartame: are new studies in the horizon?

Front Med (Lausanne)

December 2023

Department of Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.

Fatty liver disease has been on the rise in the past few decades, and there is no hope that it will stop. The terminology change that has been recently proposed may not be sufficient to advocate for a reduction of steatogenic foods and a change in lifestyle. A course change may be supported by the recent labeling of aspartame sweetener as a possible carcinogenic compound by the International Association for Research on Cancer (IARC), an agency of the World Health Organization (WHO).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!